Literature DB >> 32013319

Comparing histamine intolerance and non-clonal mast cell activation syndrome.

Nevio Cimolai1,2.   

Abstract

Entities:  

Year:  2020        PMID: 32013319      PMCID: PMC7000637          DOI: 10.5217/ir.2019.00087

Source DB:  PubMed          Journal:  Intest Res        ISSN: 1598-9100


× No keyword cloud information.
The work of Schnedl et al. [1] which assesses diagnostic clinical symptoms for histamine intolerance (HI) is an important step towards furthering the understanding of this clinical entity. What is clear from their publication, however, is that the predictive values of clinical symptoms alone are generally poor. Although they suggest assessing circulating levels of the enzyme diamine oxidase for diagnostic purposes, most patients with clinical HI do not have a deficiency of this enzyme [2,3]. Overall, the clinical presentation of HI is generally confusing. It is of note that much of the published literature on this topic arises from central Europe. The clinical symptomatology of HI, although diverse and hence confusing, has a remarkable similarity to non-clonal mast cell activation syndrome (NC-MCAS) which is gathering increasing attention, but especially in North America [4-7]. Whereas patients with severe NC-MCAS are a more definitive subset, the majority of patients with the NC-MCAS diagnosis are difficult to understand, and the entity is considerably heterogeneous from a clinical perspective [8]. NC-MCAS can be relapsing or indolent, but not as severe as more aggressive forms of mastocytosis. In both HI and NC-MCAS, dietary factors may have relevance in onset and management of disease [9]. In both HI and NC-MCAS, reliable diagnostic laboratory markers are not recognized for most patients [10]. As syndromic and spectral diagnoses, there is considerable overlap for these diseases, and both clearly concern the actions of histamine in the least. These features beckon the need for researchers in these 2 domains to come together in search of commonalities for causation, reliable laboratory markers, and treatment. Given the similarity of these 2 entities, it would seem essential for Schnedl et al. [1] to consider whether their patients, some or all, could be considered within the NC-MCAS spectrum. Likewise, it would be imperative for researchers who publish on the topic of NC-MCAS to consider whether their patients may have HI.
  10 in total

Review 1.  Mast Cell Activation Syndrome.

Authors:  Marianne Frieri
Journal:  Clin Rev Allergy Immunol       Date:  2018-06       Impact factor: 8.667

Review 2.  Doctor, I Think I Am Suffering from MCAS: Differential Diagnosis and Separating Facts from Fiction.

Authors:  Peter Valent; Cem Akin
Journal:  J Allergy Clin Immunol Pract       Date:  2019-04

Review 3.  Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management.

Authors:  Mariana Castells; Joseph Butterfield
Journal:  J Allergy Clin Immunol Pract       Date:  2019-04

4.  Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations.

Authors:  Matthew J Hamilton; Jason L Hornick; Cem Akin; Mariana C Castells; Norton J Greenberger
Journal:  J Allergy Clin Immunol       Date:  2011-05-28       Impact factor: 10.793

Review 5.  Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome.

Authors:  Peter Valent; Patrizia Bonadonna; Karin Hartmann; Sigurd Broesby-Olsen; Knut Brockow; Joseph H Butterfield; Massimo Triggiani; Jonathan J Lyons; Joanna N G Oude Elberink; Michel Arock; Dean D Metcalfe; Cem Akin
Journal:  Int Arch Allergy Immunol       Date:  2019-06-28       Impact factor: 2.749

Review 6.  Histamine intolerance: a metabolic disease?

Authors:  H G Schwelberger
Journal:  Inflamm Res       Date:  2010-03       Impact factor: 4.575

Review 7.  Histamine and histamine intolerance.

Authors:  Laura Maintz; Natalija Novak
Journal:  Am J Clin Nutr       Date:  2007-05       Impact factor: 7.045

Review 8.  Immunology and clinical manifestations of non-clonal mast cell activation syndrome.

Authors:  Juan-Carlos Cardet; Mariana C Castells; Matthew J Hamilton
Journal:  Curr Allergy Asthma Rep       Date:  2013-02       Impact factor: 4.806

Review 9.  Nonclonal Mast Cell Activation Syndrome: A Growing Body of Evidence.

Authors:  Matthew J Hamilton
Journal:  Immunol Allergy Clin North Am       Date:  2018-06-09       Impact factor: 3.479

10.  Evaluation of symptoms and symptom combinations in histamine intolerance.

Authors:  Wolfgang J Schnedl; Sonja Lackner; Dietmar Enko; Michael Schenk; Sandra J Holasek; Harald Mangge
Journal:  Intest Res       Date:  2019-03-07
  10 in total
  2 in total

1.  Oligoantigenic Diet Improves Children's ADHD Rating Scale Scores Reliably in Added Video-Rating.

Authors:  Anna Dölp; Katja Schneider-Momm; Philip Heiser; Christina Clement; Reinhold Rauh; Hans-Willi Clement; Eberhard Schulz; Christian Fleischhaker
Journal:  Front Psychiatry       Date:  2020-08-20       Impact factor: 4.157

Review 2.  Histamine Intolerance Originates in the Gut.

Authors:  Wolfgang J Schnedl; Dietmar Enko
Journal:  Nutrients       Date:  2021-04-12       Impact factor: 5.717

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.